Cappuccio Serena, Distefano Maria Grazia, Ghizzoni Viola, Fagotti Anna, Scambia Giovanni
Università Cattolica del Sacro Cuore, Istituto di Clinica Ostetrica e Ginecologica, Roma, Italy.
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Gynecol Oncol Rep. 2020 Feb 13;32:100547. doi: 10.1016/j.gore.2020.100547. eCollection 2020 May.
Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to overcome histology boundaries and to avoid unnecessary toxicity. We describe the case of a patient affected by recurrent high-grade serous ovarian cancer responsive to MEK-inhibitors, who had undergone multiple lines of therapy. To our knowledge, this is the first reported case of recurrent high-grade ovarian cancer showing remarkable clinical, radiologic and biochemical response to trametinib. This report suggests that trametinib could be effective in high-grade serous ovarian cancer, although most of promising scientific data on this molecule have focused on low-grade ovarian cancer. Molecular profiling has gradually become part of care for patients affected by recurrent ovarian cancer, however further randomized studies are needed to prove its efficacy in everyday clinical practice.
复发性卵巢癌的传统治疗失败仍然是临床医生面临的一项挑战。肿瘤基因检测是一种很有前景的工具，已被证明能够识别癌症患者的敏感性特征。这可能有助于选择靶向性全身治疗，旨在突破组织学界限并避免不必要的毒性。我们描述了一例复发性高级别浆液性卵巢癌患者对MEK抑制剂有反应的病例，该患者已经接受了多线治疗。据我们所知，这是首例报告的复发性高级别卵巢癌对曲美替尼表现出显著临床、影像学和生化反应的病例。本报告表明，曲美替尼可能对高级别浆液性卵巢癌有效，尽管关于该分子的大多数有前景的科学数据都集中在低级别卵巢癌上。分子图谱分析已逐渐成为复发性卵巢癌患者护理的一部分，然而还需要进一步的随机研究来证明其在日常临床实践中的疗效。
